PRECISION BIOSCIENCES INC
DTILPrecision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary "ARCUS" genome editing platform.
Drugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
How DTIL's past catalysts played out
NPC-1C/NEO-102
Metastatic Pancreatic Cancer
NEO-201 in combination with pembrolizumab
Non Small Cell Lung Cancer
PBGENE-DMD (IV)
Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
NPC-1C/NEO-102 | Phase 2 | Metastatic Pancreatic Cancer | - | - |
NEO-201 in combination with pembrolizumab | Phase 2 | Non Small Cell Lung Cancer | - | - |
PBGENE-DMD (IV) | Phase 2 | Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD | - | - |
Frequently asked questions
What is in PRECISION BIOSCIENCES INC's drug pipeline?→
CatalystAlert tracks 3 drug candidates in PRECISION BIOSCIENCES INC's (DTIL) pipeline across Phase 2. Its lead program is NPC-1C/NEO-102 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is PRECISION BIOSCIENCES INC's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for PRECISION BIOSCIENCES INC (DTIL) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track DTIL biotech catalysts?→
Add DTIL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow PRECISION BIOSCIENCES INC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.